Sponsor: AbbVie, Inc
Sponsor Study ID: M24-311
Study Title: A Phase 2, Randomized Study to Evaluate the Safety, Efficacy and Optimal dose of ABBV-400 in Combination with Fluorouracil (5-FU), Folinic Acid and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer (mCRC)
CTO #: 103945
NCT Number: NCT06107413
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Colon
Study Objectives: To optimize ABBV-400 dose in combination with 5-FU, folinic acid, and bevacizumab to determine the RP3D regimen for the combination. To evaluate the efficacy as measured by OR and PFS of ABBV-400 in combination with 5-FU, folinic acid, and bevacizumab, To evaluate the safety and tolerability of ABBV-400 in combination with 5-FU, folinic acid, and bevacizumab.